Next-generation antibody-drug conjugates, bispecifics, radiopharmaceuticals, tyrosine kinase inhibitors ... Fierce provides a ...

Roughly one year into launch, Lenz Therapeutics, the maker of Vizz eye drops fo | In a massive overhaul of its operating ...

Even as a wave of clinical trial wins bolsters its momentum, Merck & Co. is prioritizing ongoing pipeline and commercial ...

As the commercial momentum behind Lilly’s tirzepatide franchise continues, analysts are increasingly turning their attention ...

Saved by the Bell” actor Mark-Paul Gosselaar is the new face (and name) of AstraZeneca’s biomarker testing push, “Meet Your ...

For that indication, Rytelo is dosed at 7.1 mg/kg administered as an intravenous infusion every four weeks. Thrombocytopenia ...

Bristol Myers Squibb executives faced sharp questions from an analyst on Thursday regarding the slow commercial launch pace of its highly touted Cobenfy. | BMS' novel-mechanism schizophrenia drug, ...

Several months after telegraphing a major antibody-drug conjugate manufacturing expansion in its native Switzerland, CDMO ...

After decades of being put on the backburner, women across the U.S. are “still waiting” to trust healthcare systems, a new ...

Eli Lilly is consolidating its U.S. and international commercial divisions into a unified department, tapping current U.S.

GSK's chief executive Luke Miels has committed to a transparent communication strategy after telling analysts during its Q3 ...

Two late-stage clinical failures of high-value projects have not changed CEO Vas Narasimhan’s projection for Novartis over ...